ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $37.62M fell 38.6% year over year, behind the +5.2% change in trailing-twelve-month research & development. Sequentially, it rose 16.9% from the prior quarter. Over 3 fiscal years it compounded at +71.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.6% toward the trailing-twelve-month pace of +5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 153.35M USD
- Year-over-year change
- +94.1%
- 4-year CAGR
- +121.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 153.35M | +94.1% |
| FY2024 | 2024-12-31 | 79M | +21.8% |
| FY2023 | 2023-12-31 | 64.88M | +113.2% |
| FY2022 | 2022-12-31 | 30.43M | +373.0% |
| FY2021 | 2021-12-31 | 6.43M | — |
Research & Development vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 research & development of $129.68M is the 6th highest of the 11 companies compared; the peer median is $131.23M.
- Its year-over-year change of +5.2% is the 6th highest of 11, against a peer median of +4.2%.
- Over three fiscal years its annual growth of +71.4% compares with a peer median of +1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $824.32M | -6.8% | -2.6% | 33.8% | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Jun 2026 | $236.92M | +3.2% | -8.3% | 52.7% | |
| LTM Jun 2025 | $190.1M | -25.1% | -15.0% | 31.6% | |
| LTM Sep 2026 | $133.6M | +39.6% | -6.2% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $111.3M | +26.9% | +33.8% | — | |
| LTM Mar 2026 | $68M | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $30.06M | -37.6% | -19.5% | — | |
| Peer median (excluding AVBP) | $131.23M | +4.2% | +1.7% | 43.3% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.